Valuation: AC Immune SA

Market Cap 200M 239M 215M 181M 341M 22.71B 343M 2.4B 938M 11.79B 896M 876M 37.91B P/E 2026 *
-4.87x
P/E 2027 * 10.4x
Enterprise Value 155M 185M 167M 141M 264M 17.63B 266M 1.87B 728M 9.15B 695M 680M 29.42B EV / Sales 2026 *
8.33x
EV / Sales 2027 * 2.44x
Free-Float
56.03%
Yield 2026 *
-
Yield 2027 * -
1 week-6.33%
Current month-8.14%
1 month-7.34%
3 months+1.18%
6 months-20.70%
Current year-23.94%
1 week 2.08
Extreme 2.085
2.3
1 month 2.08
Extreme 2.085
2.56
3 years 1.28
Extreme 1.284
4.74
5 years 1.28
Extreme 1.284
9
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 65 2021-10-28
Chairman 64 2025-06-18
Change 5-day change 1-year change 3-year change Capi.($)
-2.56%-6.33%-20.56%-17.97% 239M
+3.62%+1.68%+48.80%+98.41% 1,077B
+2.13%-1.76%+33.04%+61.88% 612B
+3.32%+4.47%+23.72%+91.59% 501B
+3.80%+3.21%+73.99%+41.69% 364B
+3.09%+3.03%+29.59%+45.42% 353B
+2.82%+2.20%+17.90%+40.15% 278B
+3.40%+0.99%-3.44%+12.08% 251B
+3.21%+3.15%+45.01%+49.99% 230B
+3.80%+4.56%+29.59%+97.73% 190B
Average +3.02%+1.97%+27.76%+52.10% 428.5B
Weighted average by Cap. +2.66%+1.58%+36.85%+68.78%

Financials

2026 *2027 *
Net sales 18.66M 22.25M 20M 16.92M 31.76M 2.12B 31.96M 224M 87.46M 1.1B 83.52M 81.71M 3.53B 89.19M 106M 95.57M 80.83M 152M 10.12B 153M 1.07B 418M 5.25B 399M 390M 16.89B
Net income -42.87M -51.1M -45.94M -38.86M -72.95M -4.86B -73.41M -515M -201M -2.52B -192M -188M -8.12B 19.95M 23.78M 21.38M 18.09M 33.95M 2.26B 34.17M 239M 93.51M 1.17B 89.29M 87.35M 3.78B
Net Debt -44.8M -53.39M -48.01M -40.6M -76.23M -5.08B -76.71M -538M -210M -2.64B -200M -196M -8.48B 17.1M 20.38M 18.32M 15.5M 29.1M 1.94B 29.28M 205M 80.13M 1.01B 76.52M 74.86M 3.24B
Projected Income Statement - Annual - AC Immune SA
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
-
Date Price Change
26-10-15 €2.090 -2.56%
26-10-14 €2.145 -0.69%
26-10-13 €2.160 -1.59%
26-10-12 €2.195 -0.23%
26-10-09 €2.200 -3.72%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - AC Immune SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.014CHF
Average target price
7.113CHF
Spread / Average Target
+253.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AC Immune SA